BEK Pro Skills | Regulatory Update | Published 11 Nov 2026 · Updated 13 Nov 2026 · @Angela Blemmings
If you work with dermal fillers, you've probably heard different answers to the same three questions. Does a prescriber need to be in the room? Can hyaluronidase be prescribed in advance, just in case? And how does a non-prescriber lawfully get hold of emergency adrenaline?
Rather than add another opinion to the mix, we went to the source. On 6 November 2026, BEK Pro Skills wrote to the Medicines and Healthcare products Regulatory Agency (MHRA) and the Nursing and Midwifery Council (NMC). The NMC replied on 9 November and the MHRA on 11 November.
Here's what they confirmed, what they didn't, and what it means for your practice.
At a glance
No blanket attendance rule. NMC standards don't require a nurse independent prescriber to be physically present for every filler treatment. The level of oversight is the prescriber's call, based on risk.
No "just in case" hyaluronidase. The NMC does not regard anticipatory prescribing of hyaluronidase as safe and effective prescribing practice.
PSDs are flexible, but that's not the whole answer. The MHRA confirmed a PSD can cover off-label use and run for a period the prescriber sets. That doesn't make every arrangement appropriate.
Administering isn't the same as stocking. Adrenaline can be given to save life in an emergency. The emergency administration exemption does not, by itself, authorise practitioners to purchase or hold adrenaline as general stock. Separate lawful supply arrangements must be established. The MHRA has indicated that it plans to discuss the complexities with the CQC and DHSC.
Some nurse prescribers say they must attend every filler treatment, because a complication may need prescription-only medicines. Others say practitioners can work independently, as long as emergency arrangements are in place. We asked the NMC which is right.
The NMC confirmed there is no such requirement in its standards or guidance. The level of oversight is determined by the prescriber's professional judgement, risk assessment and the individual circumstances of the patient and situation.
Be clear on what this does and doesn't mean. It does not mean any practitioner can work without a prescriber on site, or that remote support will always be enough. It means the NMC doesn't set one fixed supervision model. The prescriber has to weigh up the practitioner's competence, the treatment, the likely complications and how quickly emergency help could be given.
This fits with Health Education England's Qualification Requirements for Cosmetic Procedures (2015), section 2.31, which places the oversight decision with the professional providing it.
Hyaluronidase is a prescription-only medicine (POM), used off-label to dissolve hyaluronic acid filler. Vascular occlusion is time-critical, so wanting it close to hand is completely understandable.
We asked whether a nurse independent prescriber could assess a named client before an elective filler treatment, prescribe hyaluronidase, and issue a PSD so a trained non-prescriber could give it if an occlusion happened.
The NMC's answer was unambiguous. It would not regard "such anticipatory prescribing in advance of something that might happen" as safe and effective prescribing practice.
One important point of scope: the NMC regulates nurses and midwives. This is its expectation of NMC registrants. It shouldn't be presented as a ruling for every prescriber, such as doctors, dentists or pharmacist independent prescribers, who answer to their own regulators.
A Patient Specific Direction (PSD) is a written instruction from a prescriber for a medicine to be supplied or administered to a named, individually assessed person. The MHRA confirmed two things:
A PSD can be used for an off-label indication, as long as the patient is assessed in line with standard PSD requirements.
A PSD can run for any validity period, as long as the prescriber specifies it.
Both points match the NHS Specialist Pharmacy Service guidance on PSDs, which the MHRA pointed us to.
It's worth knowing the limits of this answer. The MHRA told us it doesn't have specific expertise here, because professional prescribing legislation sits with the Department of Health and Social Care (DHSC). So its response describes what the PSD mechanism can legally do. It does not approve prescribing hyaluronidase in advance of a possible complication.
A PSD being legally capable of covering off-label use or a set period doesn't make every prescribing decision professionally appropriate. For NMC-registered prescribers, the NMC's response makes its professional position on the proposed anticipatory prescribing arrangement clear. However, further clarification is still needed regarding the practical arrangements for emergency medication.
We put a specific scenario to both regulators. A client is assessed and hyaluronidase is dispensed for them by name. No complication happens. Months later they come back. The medicine is unopened, in date, correctly stored and allocated only to them. Can it stay available for their next treatment?
This isn't the same as holding general stock, because the medicine never leaves that one client. But:
The MHRA did not answer this question.
The NMC said the situation "should not arise", because the anticipatory prescribing behind it shouldn't happen in the first place.
So this should not be taught or treated as an established solution. The legal questions about supplying, storing and retaining individually dispensed medicines remain open, and we've been directed to the DHSC and NHS Specialist Pharmacy Service for answers.
Under Regulation 238 and Schedule 19 of the Human Medicines Regulations 2012, certain prescription-only medicines, including adrenaline, may be administered for the purpose of saving life in an emergency.
But the legal right to give a medicine in an emergency is not the same as the right to buy, obtain or hold it as stock. We asked the MHRA what lawful routes exist for non-prescribers.
The MHRA said that, currently, advance stocks of POMs can only be obtained by:
doctors
dentists
pharmacists conducting a retail pharmacy business
organisations able to receive supplies of medicines, such as an independent hospital or clinic registered with the CQC for treatment of disease and injury (or the equivalent body in Scotland, Wales or Northern Ireland).
There are also exemptions allowing certain healthcare professionals to obtain specific medicines, set out in the MHRA's rules for specific healthcare professionals.
Importantly, the MHRA acknowledged real complexity in how the emergency administration provisions and professional exemptions interact. It has arranged to discuss this with the Care Quality Commission (CQC) and DHSC within the next few months. We'll be watching closely.
We asked the NMC what should be in place if a vascular occlusion happens while the prescriber is off site. It said this is a clinical practice matter outside its remit, so it doesn't give specific guidance on managing particular complications.
It did point to the competency framework for all prescribers, which the NMC adopted in 2018 as its baseline standard. Section 6.2 says every prescriber must establish and maintain a plan to monitor the effectiveness of treatment and potential unwanted effects. The NMC confirmed this would include complications like the ones we raised.
We also shared five areas we believe a prescriber should cover before working with a non-prescribing practitioner. The NMC doesn't issue guidance on these, but said they "would seem to be sensible things" for any prescriber to ensure before entering that kind of business relationship:
The practitioner's competence, qualifications and training
Access to appropriate emergency medicines
The prescriber's availability during complications
Written emergency protocols and escalation arrangements
Documentation, accountability and ongoing review
Although these were not presented as a formal NMC checklist, they provide useful considerations when developing professional agreements and emergency management arrangements.
The bottom line: a prescriber's phone number on file is not, on its own, an emergency plan. Arrangements need to match the treatment, the practitioner's competence and the risks involved, and they need to be agreed before the first client is booked.
The biggest lesson from these responses is that four different things often get blurred together in our industry:
Legal requirements: what medicines legislation permits or restricts.
Professional standards: what a prescriber's regulator expects of its registrants.
Clinical guidance: evidence-based recommendations for managing treatments and complications.
Individual risk assessment: decisions based on the practitioner's competence, the treatment and the emergency arrangements available.
They're connected, but they're not interchangeable. Something can be legally possible and still fall short of a prescriber's professional standards. And a professional recommendation shouldn't be described as a statutory requirement.
If you train practitioners, this means:
Teach that NMC standards do not impose a blanket requirement for prescriber attendance at every dermal filler treatment. However, the level of oversight must be determined through appropriate professional judgement, risk assessment and individual circumstances.
Don't present anticipatory hyaluronidase prescribing as an option for NMC-registered prescribers.
Keep the emergency right to administer adrenaline separate from the question of how it can be lawfully obtained and stored.
The MHRA has referred specific prescribing-policy questions to the DHSC, providing a direct contact address. NHS Specialist Pharmacy Service has explained that it cannot advise BEK Pro Skills because its service is commissioned for NHS and NHS-commissioned organisations. We are pursuing clarification on:
how emergency prescription-only medicines can be lawfully supplied and stored
the line between named-client prescribing and general emergency stock
the practical implications of the NMC's position on anticipatory hyaluronidase
workable emergency medicine arrangements for non-prescribing practitioners
any guidance that comes out of the MHRA's discussions with the DHSC and CQC.
As further responses are received and any additional regulatory guidance becomes available, BEK Pro Skills will review the information and publish relevant updates for practitioners, training providers and our approved provider network.
Following publication of this article, BEK Pro Skills received additional written clarification from the Nursing and Midwifery Council (NMC).
Anticipatory prescribing generally. The NMC's position on anticipatory prescribing is not limited to hyaluronidase or dermal filler treatments. Under its interpretation of section 18.1 of the NMC Code, prescribing must address an individual's current health needs rather than a hypothetical future complication.
Arrangements for complications. Where a nurse independent prescriber supports a non-prescribing aesthetic practitioner, arrangements must be in place to enable rapid assessment and prescribing if a complication occurs. The NMC does not prescribe a specific model for these arrangements, explaining that the practical details fall outside its regulatory remit.
No blanket attendance requirement. This clarification does not introduce a requirement for nurse independent prescribers to be physically present during every dermal filler treatment.
In further written correspondence, the NMC stated that nurses in England are not legally allowed to hold general stocks of prescription-only medicines. It explained that the restrictions on obtaining emergency POM stock are a matter of legislation, outside the NMC's remit. This is the NMC's account of the position, rather than a legal ruling on every possible clinic or organisational arrangement.
It is important to distinguish a nurse prescriber obtaining stock in their own right from a legally authorised organisation obtaining medicines for use within its service. The MHRA had previously identified certain organisations, including qualifying registered clinics, as potentially able to receive stock. Whether a particular nurse-led clinic in England could use such a route remains a question for DHSC.
The NMC also described a different arrangement in Scotland, where nurse prescribers working in certain aesthetic clinics registered with Healthcare Improvement Scotland can have access to limited emergency POM stocks. The NMC said an equivalent arrangement for nurse prescribers in England would require legislative change. We have asked DHSC to clarify the precise legal basis for the Scottish position and whether the difference relates to clinic registration, medicines legislation or both.
Separately, the NMC has reaffirmed that it does not consider anticipatory prescribing for hypothetical future complications professionally acceptable for nurse prescribers. This should not be confused with the question of whether an organisation can lawfully obtain and hold general stock.
Imagine a practitioner identifies a suspected vascular occlusion during a dermal filler treatment. The NMC expects a prescriber to assess the client and issue a prescription when the complication occurs. But several questions follow:
How quickly can that assessment take place?
Who can lawfully obtain the medicine?
Where will the medicine be available?
How will it reach the client without causing a dangerous delay?
A prescription being issued quickly does not necessarily mean the medicine will be available quickly. With a time-critical complication like vascular occlusion, that difference matters.
The NMC has placed responsibility on prescribers and practitioners to establish an effective emergency arrangement, while declining to specify what that arrangement should look like.
In regulatory terms, that isn't a contradiction. The NMC regulates professional conduct; it doesn't design emergency treatment pathways. But for independent aesthetic practitioners, it creates a very real practical difficulty.
The professional expectation is now clear. What no regulator has yet identified is a lawful medicines supply route that makes that expectation workable for most independent practitioners outside doctor-, dentist- or pharmacist-led settings. That is not the same as saying no route exists. The MHRA has acknowledged the complexity of the legislation and indicated that it intends to discuss it with the CQC and DHSC. But until that route is confirmed, the gap remains.
The MHRA has now provided a direct referral to the DHSC Prescribing Policy Team (MHRA reference CEC 271595) and clarified that its earlier comments about PSDs were general explanations of their legal use, not approval of a specific advance-prescribing arrangement.
On 13 November 2026, BEK Pro Skills sent a formal enquiry to DHSC asking it to clarify:
whether a nurse independent prescriber or appropriately registered aesthetic clinic in England has any lawful route to obtain and hold emergency hyaluronidase stock;
how medicines legislation on PSDs differs from the NMC's professional restrictions on anticipatory prescribing;
the legislative and registration basis for the arrangements described in Scotland;
what lawful supply arrangements may support timely emergency access where a prescriber is off site;
whether access to emergency medicines could be considered within future regulation of non-surgical cosmetic procedures or through a separate legislative review; and
how educators, awarding bodies and qualification developers can contribute evidence to any relevant consultation.
DHSC has not yet responded. We are not suggesting that all nurse prescribers or independent clinics have no possible lawful route, nor that any proposed reform has been agreed. The purpose of the enquiry is to obtain a clear explanation of the current position and ask whether changes should be considered in the interests of client safety.
We will update this article when a substantive response is received.
There's a lot of confident advice in aesthetics that turns out to be one person's interpretation. At BEK Pro Skills, we'd rather go straight to the regulators and share exactly what they say, including the bits that are still unclear. Good education depends on getting this right, and so does client safety.
BEK Pro Skills™ Empowering Skills. Elevating Futures. www.bekproskills.com
Important information: This article is for educational and professional awareness purposes. It is based on direct written correspondence between BEK Pro Skills and the MHRA and NMC in November 2026. These responses provide useful clarification but are not published regulatory guidance or formal policy statements, and are not intended to cover every possible situation. It does not constitute legal advice, prescribing authorisation or an approved emergency treatment protocol. Practitioners and prescribers must comply with applicable legislation, professional standards and current clinical guidance.
Medicines and Healthcare products Regulatory Agency (MHRA). Direct written correspondence with BEK Pro Skills, 11–13 November 2026, ref. CEC 271595 (not published regulatory guidance).
Nursing and Midwifery Council (NMC). Direct written correspondence with BEK Pro Skills, 9–13 November 2026 (not published regulatory guidance).
NHS Specialist Pharmacy Service. Direct response to BEK Pro Skills, November 2026 (service eligibility only; no advice on the legal question).
Department of Health and Social Care. Formal enquiry submitted by BEK Pro Skills, 13 November 2026 (response pending).
Health Education England (2015). Qualification Requirements for Cosmetic Procedures, section 2.31.
Royal Pharmaceutical Society. A Competency Framework for All Prescribers, section 6.2 (adopted by the NMC in 2018).
NHS Specialist Pharmacy Service. Patient Specific Directions (PSD).
MHRA. Rules for the sale, supply and administration of medicines for specific healthcare professionals.